NEW YORK, Dec. 2 Reportlinker.com announces that a new market research report is available in its catalogue:
Hepatitis C Virus And Therapeutics - A Global Update of Market Trends & Opportunities
Advertisement
http://www.reportlinker.com/p0164272/Hepatitis-C-Virus-And-Therapeutics---A-Global-Update-of-Market-Trends--Opportunities.html
Bucking the trend witnessed for all these years of meager clinical outcomes owing to lack of superior therapies, research & development in hepatitis C virus therapeutics market is on the verge of a major breakthrough. The Hepatitis C Virus (HCV) therapeutics development landscape continues to inflate and currently possesses three compounds in Phase III clinical studies, several novel therapies in Phase II and Phase I pipeline, and numerous new compounds in animal-stage study and research stages. Along with immunomodulators, long acting/oral interferons, and direct acting anti-viral therapies, new compounds represented by several other drug categories, including Polymerase/Protease Inhibitors, MicroRNA, TLR9 agonists, NS5A Inhibitors, Cyclophilin inhibitors, A3AR Agonists, and vaccines among others, would be successfully developed to expand the scope of HCV treatment.
Advertisement
These and other market data and trends are presented in "Hepatitis C Virus And Therapeutics: A Global Update of Market Trends & Opportunities" by BizAcumen, Inc. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses.
HEPATITIS C VIRUS AND THERAPEUTICS BMR-1072
CONTENTS
1. METHODOLOGY 1
Study Reliability and Reporting Limitations 1
Disclaimers 2
Quantitative Techniques & Reporting Level 3
2. GLOBAL MARKET OVERVIEW AND OUTLOOK 3
Pegylated Alpha Interferon Plus Ribavirin - The Standard Therapy 5
Approved Drugs for HCV Combination Therapy 5
Alpha Interferons and Ribavirin are Here to Stay 5
Interferon-based Drugs in Pipeline by Company and Development
Stage 6
Albuferon - Rising Above the Standards 6
Viramidine - Next-Generation Ribavirin Drug 6
High Mutation Rates Keep HCV Elusive 7
Genotype I - Least Responsive and Most Common Variant of HCV 7
Protease Inhibitors (PIs) - Way Above Others 7
Protease Inhibitor Drugs in Pipeline by Company and
Development Stage 8
SCH 900518 - Schering's Next-Generation Protease Inhibitor 8
Telaprevir (VX-950) - The Most Promising Pipeline HCV
Protease Inhibitor 9
Boceprevir - Schering's PI Class Lead Candidate 9
Comparison Between Telaprevir and Boceprevir 10
Telaprevir and Boceprevir - A Comparison 11
Polymerase Inhibitors (PLIs) - Adding More Teeth to HCV Pipeline 11
Viral Polymerases 11
Polymerase Inhibitor Drugs in Pipeline by Company, Category,
and Development Stage 12
R7128 - A Promising PLI Class Drug 12
Development of PLIs Remains a Challenge for HCV Researchers 13
Industry in Search of Novel STAT-C Drugs 13
Specific Antiviral Activity of Select HCV Drug Classes 14
Select NS5A Inhibitors, Entry Inhibitors, and Thiazolides in
Pipeline by Company and Development Stage 14
Researchers Show Continued Appetite for Immunomodulators and
Other Classes 15
Immunomodulators in Pipeline by Company, and Development Stage 15
Adjuvant Therapies to Compete with Mainline Therapies 15
Cyclophilin Analogs and Fibrosis/ Inflammation Inhibitors in
Pipeline by Company 16
Vaccine Development Remains at Low Scale 16
HCV Vaccines in Pipeline by Company, and Development Stage 16
Decisive Factors For Success of New HCV Therapeutics 17
HCV Treatment Costs to Escalate 17
Roche & Schering - Dominant Players in HCVTherapeutics Market 17
HCV Drugs from Roche & Schering 18
Partnerships in R&D Become Order of the Day 18
Select Partnership Deals in HCV DrugDevelopment Programs 19
Market Drivers/Constraints 20
Treatment-Experienced Patients - A Potential Opportunity for
Developers 20
Education Campaigns to Magnify Patient Diagnosis Rates 20
Stigmatization and Discrimination - Major Hurdles for HCV
Treatment 21
Treatment with Current Therapies Plagued by Side Effects 21
Hemolytic Anemia - A Key Side Effect with Ribavirin 21
Epidemiology 21
Quick Facts about HCV Infection 21
Low-Treatment Rates vis-à-vis Patient Population 22
Factors Influencing HCV Treatment Market 23
Drivers 23
Bottle Necks 23
3. HCV MEDICATION - APPROVED & PIPELINE DRUGS 23
Approved Drugs for HCV Treatment 23
Interferons - The Backbone of HCV Treatment 23
Intron® A 24
Roferon A 24
Infergen 24
PEG-Intron® 24
Pegasys 24
FDA Approval of Interferons for Use as Monotherapy in
Chronic Hepatitis C Treatment 25
Ribavirin - Antiviral Drug for HCV Treatment 25
Rebetol® 25
Copegus 25
Drugs in Pipeline for HCV Treatment 26
Select HCV Drugs Under Pipeline (Phase III/Phase II) by Company 27
Select HCV Drugs Under Pipeline (Phase I) by Company 28
Select HCV Drugs in Pre-Clinical/Research Stage by Company 29
Select HCV Drugs with Cancelled Clinical Studies by Company 30
4. PRODUCT FACTS 31
Hepatitis C Virus 31
5. REGIONAL PERSPECTIVE 31
United States 31
HCV Infection - Ethnicity 32
African-Americans React Poorly to Treatment 32
Genotype 1 - The Most Prevalent HCV Strain 33
Falling HCV Incidences in the US 33
Canada 33
Australia 34
India 35
Egypt 35
France 36
The Netherlands 36
HCV Infection Prevalence in Risk Groups in the Netherlands 37
Central and Eastern Europe 37
HCV Prevalence Rate Higher in Injection Drug Users 37
Alarming Rates of HIV/HCV Co-Infection 37
Testing and Counseling Structure Poorly Developed 37
Depleted Testing Schemes for Prisoners 38
Scarcity Prevails at Health Care Providers and Governments As
Well 38
Practical Availability of PEG-IFN Remains Limited 38
Dearth in Political Commitment 38
HCV Diagnostic Tests and Treatment in Select CEE Countries 39
Bulgaria 39
Czech Republic 39
Hungary 39
Romania 40
Russia 40
Ukraine 40
Availability of Testing Protocols for HCV in Select CEE
Countries 41
6. CORPORATE DEVELOPMENTS 42
Three Rivers Acquires Infergen® 42
International Consolidated Cos Takes Over China Gene 42
Hologic Signs Definitive Deal to Acquire Third Wave 42
GlaxoSmithKline Inks Deal to Take Over Genelabs 42
Biolex Signs Deal to Purchase OctoPlus' Stake in Locteron® 43
OraSure and Schering-Plough Form Global Alliance 43
Tacere and Oncolys Sign Licensing Agreement 43
Beckman Wins HCV Diagnostics Rights from Siemens Healthcare 44
Anadys Secures FDA Fast Track Designation for its Lead Drug
Candidate 44
Roche Bags European Commission Approval for Combination Therapy 44
Roche Receives European Commission Approval for Shortened
Hepatitis C Therapy 44
iTherX Establishes Advisory Board for Hepatitis C Advanced
Therapeutics 45
SciClone Terminates Zadaxin® 45
Vertex to Initiate Phase III Trial of Telaprevir 45
Amarillo and CytoPharm to Initiate Phase II Study of Novel
Oral Interferon 45
Biolex Releases Locteron® Phase IIa Trial Results 46
Schering-Plough Releases Details of Boceprevir Phase II Study 46
Progenics Releases Pre-Clinical Results of PRO 206 47
ZymoGenetics Reveals Phase Ib Results of IL-29 47
Phenomix Begins Phase Ia Study of PHX1766 48
Inovio and Tripep Release Additional Interim Results for
ChronVac-C® 48
InterMune Starts Clinical Study of ITMN-191 49
Roche and Associates Commence Clinical Trial of All-Oral Dual
-Antiviral Therapy 49
GlobeImmune Announces Phase II Clinical Trials with GI-5005 50
AstraZeneca Acquires Arrow Therapeutics 50
Cubist Takes Over Illumigen 50
China Medical to Take Over Beijing Bio-Ekon 51
Schering-Plough Collaborates with OraSure 51
Pro-Pharmaceuticals to Collaborate with Digna Biotech 51
Medivir and Tibotec Establish Collaboration Deal 52
VGX Extends Collaboration with University of Pennsylvania 52
Presidio Wins Exclusive License to Novel HCV Technology 52
Roche Inks Licensing Deal with Novartis and Ortho-Clinical 52
Peregrine Opens Subsidiary in China 52
InterMune Completes Production Milestone 53
Arrow Expands Hepatitis C Pipeline 53
Roche Wins Japanese Approval for Combination Therapy 53
Schering-Plough Bags European Commission Approval for
Combination Therapy 53
Abbott Bags FDA Approval for Screening Test 53
Abbott Bags Canadian Approval for Viral Load Tests 54
Phynova Bags FDA Approval for IND Application 54
Worldwide Biotech Bags Chinese FDA Approval for HCV Diagnostic
Kit 54
Tibotec Applies to European Regulator to Initiate Phase I Trials 54
Roche Submits Application for Novel Hepatitis C to with FDA 55
Anadys Discontinues ANA975 55
Cerus Bags NIH Funding for HCV Vaccine Program 55
Human Genome Gets Encouraging Interim Results with Albuferon 55
Intarcia Releases Study Results of Omega Interferon 55
Nautilus Biotech Commences Phase I Study for Belerofon® 56
Migenix Announces Phase II Proof-of-Concept Study Results of
Celgosivir 56
Pharmasset Begins Multiple Dose-Escalating Study of R7128 57
Transgene Commences Phase I Trial of TG4040 57
Debiopharm Releases Phase Ib Results of Debio 025 57
Nabi Biopharmaceuticals Starts Proof-Of- Concept Trial for
Civacir 57
Peregrine Announces Positive Results for Bavituximab 58
7. MAJOR PLAYERS 59
Abbott Diagnostics (USA) 59
Achillion Pharmaceuticals, Inc. (USA) 59
Anadys Pharmaceuticals, Inc. (USA) 59
Boehringer Ingelheim GmbH (Germany) 59
Bristol-Myers Squibb Company (USA) 59
F. Hoffmann-La Roche Ltd. (Switzerland) 60
GlaxoSmithKline plc (UK) 60
Hayashibara Biochemical Labs, Inc. (Japan) 60
HemispheRx Biopharma, Inc. (USA) 60
Human Genome Sciences (USA) 60
Idenix Pharmaceuticals, Inc. (USA) 61
Innogenetics NV (Belgium) 61
InterMune, Inc. (USA) 61
Intarcia Therapeutics, Inc. (USA) 61
Medivir AB (Sweden) 61
Merck & Co., Inc. (USA) 62
Novartis AG (Switzerland) 62
Chiron Corporation (USA) 62
Pfizer, Inc. (USA) 62
Schering-Plough Corporation (USA) 62
Tibotec Pharmaceuticals Ltd. (Ireland) 63
Tripep AB (Sweden) 63
Toray Industries, Inc. (Japan) 63
Valeant Pharmaceuticals International (USA) 63
Vertex Pharmaceuticals, Inc. (USA) 63
EXHIBITS
Table 1: Global Hepatitis C Virus Therapeutics Market:
2007-2015 (Sales in US$ Million)
Table 2: Prevalence and Incidence Rate of HCV Infected
Population by Select Country in the World - 2006
Table 3: Annual Sales of Select Interferons & Ribavirins
offered by Major Players in the Global HCV Therapeutics Market
- 2008 (In US$ Million)
Table 4: HCV Infection in the US: Number of Infected People
for the Year 2008 (in '000s)
Table 5: Percentage Breakdown of Infection Sources by Medium
in the US HCV Market - 2007
Table 6: HCV Prevalence by Genotype in the US - 2005 (In %)
Table 7: Market Shares of HCV Infection Transmission Modes in
Australia
COMPANIES PROFILED
To order this report:
Therapy Industry: Hepatitis C Virus And Therapeutics - A Global Update of Market Trends & Opportunities
More Market Research Report
Contact:Nicolas BombourgReportlinkerEmail: [email protected]: (805)652-2626Intl: +1 805-652-2626
SOURCE Reportlinker
